News8 months ago
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
Ceapro Inc. – Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan...